Stem cell-mediated muscle regeneration and repair in aging and neuromuscular diseases

European Journal of Histochemistry

Volumn 51, Issue SUPPL.1, 2007, Pages 35-44

  Musarò, Antonio ^a,b   Giacinti, C ^a   Pelosi, L ^a   Dobrowolny, G ^a   Barberi, L ^a   Nardis, C ^a   Coletti, D ^a   Scicchitano, B M ^a   Adamo, S ^a   Molinaro, M ^a  

^a SAPIENZA UNIVERSITY OF ROME   (Italy)

^b EDITH COWAN UNIVERSITY   (Australia)

Author keywords

IGF 1; Oxytocin; Satellite cell; TNF ; Vasopressin

Indexed keywords

SOMATOMEDIN C; TUMOR NECROSIS FACTOR ALPHA; VASOPRESSIN DERIVATIVE;

AGING; ANIMAL; CELL DIFFERENTIATION; HUMAN; METABOLISM; NEUROMUSCULAR DISEASE; PATHOPHYSIOLOGY; PHYSIOLOGY; REGENERATION; REVIEW; SKELETAL MUSCLE; STEM CELL;

AGING; ANIMALS; CELL DIFFERENTIATION; HUMANS; INSULIN-LIKE GROWTH FACTOR I; MUSCLE, SKELETAL; NEUROMUSCULAR DISEASES; REGENERATION; STEM CELLS; TUMOR NECROSIS FACTOR-ALPHA; VASOPRESSINS;

EID: 35148883490     PISSN: 1121760X     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (72)

1. Acharyya S, Butchbach ME, Sahenk Z, Wang H, Saji M, Carathers M, et al. Dystrophin glycoprotein complex dysfunction: a regulatory link between muscular dystrophy and cancer cachexia. Cancer Cell 2005; 8:421-32.
2. Alexander SL, Irvine CH, Ellis MJ, Donald RA. The effect of acute exercise on the secretion of corticotropin-releasing factor, arginine vasopressin, and adrenocorticotropin as measured in pituitary venous blood from the horse. Endocrinology 1991; 128:65-72.
3. Alvisi M, Ciccone L, Palombi V, Alessandrini M, Molinaro M, Adamo S, Naro F. V1a vasopressin receptor expression is modulated during myogenic differentiation. Submitted for publication.
4. Argiles JM, Lopez-Soriano FJ. The role of cytokines in cancer cachexia. Med Res Rev 1999; 19:223-48.
5. Bach AD, Arkudas A, Tjiawi J, Polykandriotis E, Kneser U, Horch RE, et al. A new approach to tissue engineering of vascularized skeletal muscle. J Cell Mol Med 2006; 10:716-726.
6. Bach AD, Beier JP, Stern-Staeter J, Horch RE. Skeletal muscle tissue engineering. J Cell Mol Med 2004; 8:413-22.
7. Barberis C, Mouillac B, Durroux T. Structural bases of vasopressin/oxytocin receptor function. J Endocrinol 1998; 156:223-9.
8. Barton ER, Morris L, Musarò A, Rosenthal N, Sweeney HL. Musclespecific expression of insulin-like growth factor I counters muscle decline in mdx mice. J Cell Biol 2002; 157:137-48.
9. Barton-Davis ER, Shoturma DI, Musarò A, Rosenthal N, Sweeney HL. Viral mediated expression of insulin-like growth factor I blocks the aging-related loss of skeletal muscle function. Proc Natl Acad Sci U S A 1998; 95:15603-7.
10. Beauchamp JR, Morgan JE, Pagel CN, Partridge TA. Dynamics of myoblast transplantation reveal a discrete minority of precursors with stem cell-like properties as the myogenic source. J Cell Biol 1999; 144:1113-22.
11. Blau HM, Brazelton TR, Weimann JM. The evolving concept of a stem cell: entity or function? Cell 2001; 105:829-41.
12. Breton C, Haenggeli C, Barberis C, Heitz F, Bader CR, Bernheim L, Tribollet E. Presence of functional oxytocin receptors in cultured human myoblasts. J Clin Endocrinol Metab 2002; 87:1415-8.
13. Camargo FD, Green R, Capetanaki Y, Jackson KA, Goodell MA. Single hematopoietic stem cells generate skeletal muscle through myeloid intermediates. Nat Med 2003; 9:1520-7.
14. Chang PS, Li L, McAnally J, Olson EN. Muscle specificity encoded by specific serum response factor-binding sites. J Biol Chem 2001; 276:17206-12.
15. Charge SB, Rudnicki MA. Cellular and molecular regulation of muscle regeneration. Physiol Rev 2004; 84:209-38.
16. Coletti D, Moresi V, Adamo S, Molinaro M, Sassoon D. Tumor Necrosis Factor-gene transfer induces cachexia and inhibits muscle regeneration. Genesis 2005; 43:120-8.
17. Coletti D, Palleschi S, Silvestroni L, Tomei F, Molinaro M, Adamo S. Surface remodeling associated with vasopressin-induced membrane traffic in L6 myogenic cells. Arch Histol Cytol 2000a; 63:441-9.
18. Coletti D, Silvestroni L, Naro F, Molinaro M, Adamo S, Palleschi S. Vesicle-mediated phosphatidylcholine reapposition to the plasma membrane following hormone-induced phospholipase D activation. Exp Cell Res 2000b; 256:94-104.
19. Coletti D, Yang E, Marazzi G, Sassoon D. TNFalpha inhibits skeletal myogenesis through a PW1-dependent pathway by recruitment of caspase pathways. EMBO J 2002; 21:631-42.
20. Conboy IM, Conboy MJ, Smythe GM, Rando TA. Notch-mediated restoration of regenerative potential to aged muscle. Science 2003; 302:1575-7.
21. Conboy IM, Conboy MJ, Wagers AJ, Girma ER, Weissman IL, Rando TA. Rejuvenation of aged progenitor cells by exposure to a young systemic environment. Nature 2005; 433:760-4.
22. Convertino VA, Keil LC, Bernauer EM, Greenleaf JE. Plasma volume, osmolality, vasopressin, and renin activity during graded exercise in man. J Appl Physiol 1981; 50:123-8.
23. Cornelison DD, Wold BJ. Single-cell analysis of regulatory gene expression in quiescent and activated mouse skeletal muscle satellite cells. Dev Biol 1997; 191:270-83.
24. Cossu G, Bianco P. Mesoangioblasts--vascular progenitors for extravascular mesodermal tissues. Curr Opin Genet Dev 2003; 13:537-42.
25. De Arcangelis V, Coletti D, Conti M, Lagarde M, Molinaro M, Adamo S, et al. IGF-I-induced differentiation of L6 myogenic cells requires the activity of cAMP-phosphodiesterase. Mol Biol Cell 2003; 14:1392-404.
26. Dobrowolny G, Giacinti C, Pelosi L, Nicoletti C, Winn N, Barberi L, et al. Muscle expression of a local Igf-1 isoform protects motor neurons in an ALS mouse model. J Cell Biol 2005; 168:193-9.
27. Ferrari G, Stornaiuolo A, Mavilio F. Failure to correct murine muscular dystrophy. Nature 2001; 411:1014-5.
28. Grounds MD. Myoblast transfer therapy in the new millennium. Cell Transplant 2000; 9:485-7.
29. Guerette B, Skuk D, Celestin F, Huard C, Tardif F, Asselin I, et al. Prevention by anti-LFA-1 of acute myoblast death following transplantation. J Immunol 1997; 159:2522-31.
30. Guttridge DC, Mayo MW, Madrid LV, Wang CY, Baldwin AS, Jr. NFkappaB-induced loss of MyoD messenger RNA: possible role in muscle decay and cachexia. Science 2000; 289:2363-6.
31. Hanley MR, Benton HP, Lightman SL, Todd K, Bone EA, Fretten P, Palmers S, Kirk CJ, Michell RH. A vasopressin-like peptide in the mammalian sympathetic nervous system. Nature 1984; 309:258-61.
32. Hodgetts SI, Beilharz MW, Scalzo AA, Grounds MD. Why do cultured transplanted myoblasts die in vivo? DNA quantification shows enhanced survival of donor male myoblasts in host mice depleted of CD4+ and CD8+ cells or Nk1.1+ cells. Cell Transplant 2000; 9:489-502.
33. Hodgetts SI, Grounds MD. Irradiation of dystrophic host tissue prior to myoblast transfer therapy enhances initial (but not long-term) survival of donor myoblasts. J Cell Sci 2003; 116:4131-46.
34. Kaplan-Albuquerque N, Garat C, Van P, V, Nemenoff RA. Regulation of SM22 alpha expression by arginine vasopressin and PDGF-BB in vascular smooth muscle cells. Am J Physiol Heart Circ Physiol 2003; 285:H1444-H1452.
35. LaBarge MA, Blau HM. Biological progression from adult bone marrow to mononucleate muscle stem cell to multinucleate muscle fiber in response to injury. Cell 2002; 111:589-601.
36. Li L, Heller-Harrison R, Czech P, Olson E. Cyclic AMP-dependent protein kinase activity inhibits the activity of myogenic helix-loop-helix proteins. Mol Cell Biol 1992; 12:4478-85.
37. Louboutin JP, Fichter-Gagnepain V, Thaon E, Fardeau M. Morphometric analysis of mdx diaphragm muscle fibres. Comparison with hindlimb muscles. Neuromuscul Disord 1993; 3:463-9.
38. Mauro A. Satellite cell of skeletal muscle fibers. J Biophys Biochem Cytol 1961; 9:493-5.
39. Melin B, Eclache JP, Geelen G, Annat G, Allevard AM, Jarsaillon E, et al. Plasma AVP, neurophysin, renin activity, and aldosterone during submaximal exercise performed until exhaustion in trained and untrained men. Eur J Appl Physiol Occup Physiol 1980; 44:141-51.
40. Melin B, Jimenez C, Savourey G, Bittel J, Cottet-Emard JM, Pequignot JM, Allevard AM, Gharib C. Effects of hydration state on hormonal and renal responses during moderate exercise in the heat. Eur J Appl Physiol Occup Physiol 1997; 76:320-7.
41. Miller SC, Ito H, Blau HM, Torti FM. Tumor necrosis factor inhibits human myogenesis in vitro. Mol Cell Biol 1988; 8:2295-301.
42. Minotti S, Scicchitano BM, Nervi C, Scarpa S, Lucarelli M, Molinaro M, Adamo S. Vasopressin and insulin-like growth factors synergistically induce myogenesis in serum-free medium. Cell Growth Diff 1998; 9:155-64.
43. Miska EA, Langley E, Wolf D, Karlsson C, Pines J, Kouzarides T. Differential localization of HDAC4 orchestrates muscle differentiation. Nucleic Acids Res 2001; 29:3439-47.
44. Morgan JE, Gross JG, Pagel CN, Beauchamp JR, Fassati A, Thrasher AJ, et al. Myogenic cell proliferation and generation of a reversible tumorigenic phenotype are triggered by preirradiation of the recipient site. J Cell Biol 2002; 157:693-702.
45. Morrison J, Lu QL, Pastoret C, Partridge T, Bou-Gharios G. T-celldependent fibrosis in the mdx dystrophic mouse. Lab Invest 2000; 80:881-91.
46. Musarò A, Dobrowolny G, Rosenthal N. The neuroprotective effects of a locally acting IGF-1 isoform. Exp Gerontol 2006.
47. Musarò A, Giacinti C, Borsellino G, Dobrowolny G, Pelosi L, Cairns L, et al. Stem cell-mediated muscle regeneration is enhanced by local isoform of insulin-like growth factor 1. Proc Natl Acad Sci USA 2004; 101:1206-10.
48. Musarò A, McCullagh K, Paul A, Houghton L, Dobrowolny G, Molinaro M, et al. Localized Igf-1 transgene expression sustains hypertrophy and regeneration in senescent skeletal muscle. Nat Genet 2001; 27:195-200.
49. Naro F, Aprile L, Adamo S, Papa F, Bianchetti M, Zolla L. Effects of arg-vasopressin on developing skeletal muscle. It J Biochem 1994; 43:96A-98A.
50. Naro F, De A, V, Sette C, Ambrosio C, Komati H, Molinaro M, et al. A bimodal modulation of the cAMP pathway is involved in the control of myogenic differentiation in l6 cells. J Biol Chem 2003; 278:49308-15.
51. Naro F, Donchenko V, Minotti S, Zolla L, Molinaro M, Adamo S. Role of phospholipase C and D signalling pathways in vasopressin-dependent myogenic differentiation. J Cell Physiol 1997; 171:34-42.
52. Naro F, Sette C, Vicini E, De Arcangelis V, Grange M, Conti M, et al. Involvement of type 4 cAMP phosphodiesterase in the myogenic differentiation of L6 cells. Mol Biol Cell 1999; 10:4355-4367.
53. Némoz G, Sette C, Conti M. Selective activation of rolipram-sensitive, cAMP-specific phosphodiesterase isoforms by phosphatidic acid. Mol Pharmacol 1997; 51:242-9.
54. Nervi C, Benedetti L, Minasi A, Molinaro M, Adamo S. Arginine-vasopressin induces differentiation of skeletal myogenic cells and upregulates myogenin and myf-5. Cell Growth Diff 1995; 6:81-9.
55. Pelosi L, Giacinti C, Nardis C, Borsellino G, Rizzuto E, Nicoletti C, et al. Local expression of IGF-1 accelerates muscle regeneration by rapidly modulating inflammatory cytokines and chemokines. FASEB J. In press.
56. Relaix F, Wei X, Li W, Pan J, Lin Y, Bowtell DD, Sassoon DA, Wu X. Pw1/Peg3 is a potential cell death mediator and cooperates with Siah1a in p53-mediated apoptosis. Proc Natl Acad Sci USA 2000; 97:2105-2110.
57. Sampaolesi M, Blot S, D'Antona G, Granger N, Tonlorenzi R, Innocenzi A, et al. Mesoangioblast stem cells ameliorate muscle function in dystrophic dogs. Nature 2006; 444:574-579.
58. Sampaolesi M, Torrente Y, Innocenzi A, Tonlorenzi R, D'Antona G, Pellegrino MA, et al. Cell therapy of alpha-sarcoglycan null dystrophic mice through intra-arterial delivery of mesoangioblasts. Science 2003; 301:487-92.
59. Schultz E, Lipton BH. Skeletal muscle satellite cells: changes in proliferation potential as a function of age. Mech Ageing Dev 1982; 20:377-83.
60. Schwarzkopf M, Coletti D, Sassoon D, Marazzi G. Muscle cachexia is regulated by a P53-PW1/Peg3 dependent pathway. Genes Dev. In press.
61. Scicchitano BM, Spath L, Musarò A, Molinaro M, Adamo S, Nervi C. AVP induces myogenesis through the transcriptional activation of the myocyte enhancer factor 2. Mol Endocrinol 2002; 16:1407-16.
62. Scicchitano BM, Spath L, Musarò A, Molinaro M, Rosenthal N, Nervi C, Adamo S. Vasopressin-dependent myogenic cell differentiation is mediated by both Ca2+/calmodulin-dependent kinase and calcineurin pathways. Mol Biol Cell 2005; 16:3632-41.
63. Smith A, Stephen RJ, Arkley MM, McIntosh N. Immunoreactive arginine vasopressin in human fetal and neonatal skeletal muscle. Early Hum Dev 1992; 28:215-22.
64. Smythe GM, Hodgetts SI, Grounds MD. Problems and solutions in myoblast transfer therapy. J Cell Mol Med 2001; 5:33-47.
65. Stupka N, Gregorevic P, Plant DR, Lynch GS. The calcineurin signal transduction pathway is essential for successful muscle regeneration in mdx dystrophic mice. Acta Neuropathol (Berl) 2004; 107:299-310.
66. Szalay K, Razga Z, Duda E. TNF inhibits myogenesis and downregulates the expression of myogenic regulatory factors myoD and myogenin. Eur J Cell Biol 1997; 74:391-8.
67. Teti A, Naro F, Molinaro M, Adamo S. Transduction of the argininevasopressin signal in skeletal myogenic cells. Am J Physiol 1993; 265 (C34):C113-C121.
68. Thibonnier M, Graves MK, Wagner MS, Auzan C, Clauser E, Willard HF. Structure, sequence, expression, and chromosomal localization of the human V1a vasopressin receptor gene. Genomics 1996; 31:327-34.
69. Tisdale MJ. Cachexia in cancer patients. Nat Rev Cancer 2002; 2:862-71.
70. Wakelam MJ, Pette D. The control of glucose 1,6-bisphosphate by developmental state and hormonal stimulation in cultured muscle tissue. Biochem J 1982; 204:765-9.
71. Wakelam MJO, Patterson S, Hanley MR. L6 skeletal muscle cells have functional V1 vasopressin receptors coupled to stimulated inositol phospholipid metabolism. FEBS Lett 1987; 210:181-4.
72. Winter B, Braun T, Arnold HH. cAMP-dependent protein kinase represses myogenic differentiation and the activity of the musclespecific helix-loop-helix transcription factors Myf-5 and MyoD. J Biol Chem 1993; 268:9869-78.